The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle

scientific article published on 01 January 1984

The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/BF00257121
P698PubMed publication ID6467500

P50authorAtholl JohnstonQ53067237
Vernon HarveyQ126720724
P2093author name stringP Turner
P F Wrigley
M L Slevin
M J Barnett
R C Woollard
P2860cites workHigh dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activityQ38579498
The clinical pharmacology of methotrexate.new applications of an old drugQ39716312
Comparison of serum concentrations of methotrexate after various routes of administrationQ43982160
Enhancement of methotrexate absorption by subdivision of doseQ44147246
Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?Q51657521
Effect of route of administration and effusions on methotrexate pharmacokinetics.Q54451334
Outpatient chemotherapy for breast cancerQ66876992
Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumoursQ66904658
Assay of Therapeutic Doses of Methotrexate in Body Fluids of Patients with PsoriasisQ66919758
Bioavailability of methotrexate: implications for clinical useQ66992156
The metabolic fate of tritiated methotrexate. II. Absorption and excretion in manQ68552830
Blood Levels of Methotrexate and the Treatment of PsoriasisQ70569950
Clinical pharmacology of intermediate-dose oral methotrexateQ71236275
STRIPE: an interactive computer program for the analysis of drug pharmacokineticsQ71245588
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemiaQ72063971
Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung — A randomised trialQ72415984
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)Q72725584
The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in manQ74786929
P433issue2
P921main subjectbioavailabilityQ461809
chemotherapyQ974135
P304page(s)91-94
P577publication date1984-01-01
P1433published inCancer Chemotherapy and PharmacologyQ326137
P1476titleThe bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle
P478volume13

Reverse relations

cites work (P2860)
Q38396089Cancer chemotherapy in infants and children
Q69912783Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid
Q68758237Methotrexate bioavailability after oral and intramuscular administration in children
Q39768346Pharmacokinetics of anticancer drugs in children
Q67989804Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations

Search more.